Herbert Irving Comprehensive Cancer Center (Columbia University)
Columbia University Medical Center
New York, NY
Accepting patients
EXCALIBER - Maintenance
Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
- CELMoD
- Randomization
- Post-Autologous Stem Cell Transplant
- Phase 3
Accepting patients
Linvoseltamab
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Accepting patients
LINKER-MM4
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1/2
- Has results
Accepting patients
LimiTec
Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 2
- Has results
- Proteasome Inhibitor
- Minimal Residual Disease (MRD)
- Randomization
- Phase 2
Accepting patients
Isatuximab During Stem Cell Transplant
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
- Monoclonal Antibody
- CD38
- Post-Autologous Stem Cell Transplant
- Pre-Autologous Stem Cell Transplant
- Phase 2
Accepting patients
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Monoclonal Antibody
- CD38
- Randomization
- Maintenance
- Phase 3
Accepting patients
Early Detection Blood Tests
Blinded Reference Set for Multicancer Early Detection Blood Tests
- Observational Trial